Description
Reach new lengths and treat more diseased vein with VenaSeal™ closure system. The VenaSeal™ closure system delivers immediate and lasting vein closure with its proprietary medical adhesive formula, with a demonstrated 94.6% closure rate at five years.1-5
Maximize length of treated vein.
- Access the most distal point of reflux with no risk of thermal injury.1
- A moderate correlation was demonstrated between diseased vein treatment length and symptom improvement.†,6
- Physicians observed a decreased time to wound healing with VenaSeal™ closure system compared to radiofrequency ablation.7
Maximize patient comfort and recovery.
- Minimized pain, tenderness, and ecchymosis compared to endothermal ablation8
- Rapid return to work and normal activities3
- No post-procedure compression stockings‡,2,4
Maximize efficiencies.
- More predictable workflow than endothermal therapies with fewer unplanned visits9
- Simple, segmental procedure1
- Single, double, and triple segment treatment options
Get great outcomes.
- 94.6% vein closure at five years5
- 0 DVT (deep vein thrombosis)5
- 0 PE (pulmonary embolism)5
- Significant improvements in quality of life10
TM* Third-party brands are trademarks of their respective owners.
† Demonstrated in C2–C4 patients.
‡ Some patients may benefit from the use of compression stockings post-procedure.
- Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. 2015;61(4):985–994.
- Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European Multicenter Cohort Study on cyanoacrylate embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2021;9(2):329–334.
- Gibson K, Ferris B. Cyanoacrylate closure of incompetent great, small and accessory saphenous veins without the use of post-procedure compression: Initial outcomes of a post-market evaluation of the VenaSeal system (the WAVES Study). Vascular. 2017;25(2):149–156.
- Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2017;5(5):658–666.
- Morrison N, Gibson K, Vasquez M, Weiss R, Jones A. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2020;8(6):978–989.
- Morrison N, Gibson, Vasquez M, et al. VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. J Vasc Surg. 2017;5(3):321–330.
- Morrison, N. VenaSeal closure system vs. radiofrequency ablation for incompetent great saphenous veins (VeClose). 36-month results presented at: IVC; April 20, 2017; Miami, FL.
- Proebstle TM, Alm BJ, Gockeritz O, et al. Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. Br J Surg. 2015;102(3):212–218.
- Gibson K, Glorieux K. VenaSeal versus ablation with endothermal laser or radiofrequency for saphenous vein incompetence: a comparison of utilization of adjunctive phlebectomy (VenaSeal value). Presented at AVLS 2019. Abstract available at: journals.sagepub.com/doi/full/10.1177/0268355519893876. Accessed November 5, 2021.
- Morrison N, Gibson K, Vasquez M, et al. VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. J Vasc Surg. 2017;5(3):321–330.
Not what you're looking for?
Find more information, including other available configurations, for VenaSeal™ closure system.